Skip to main content
padlock icon - secure page this page is secure

T-Cell-Targeted Biologicals for Psoriasis

Buy Article:

$68.00 + tax (Refund Policy)

Psoriasis is now accepted as a T-cell-mediated disease and that targeting of T cell function and / or trafficking is a logical approach to therapy. As a consequence of recombinant DNA technologies biologic therapies are synthesisable in sufficient quantities for clinical use. The original proof of concept for T-celltargeted therapies in psoriasis came with the demonstration that anti-CD4 monoclonal antibodies were effective. Progress is such that two T-cell-directed biologicals - alefacept and efalizumab - have recently been approved in the U.S.A. for the treatment of psoriasis. In addition to providing new therapies the T-cell-targeted biologicals with their selective approach can be used as sophisticated tools to dissect out and help our understanding of key pathomechanisms in psoriasis; the non - efficacy of anti - E-selectin is a case in point. It is likely that the most appropriate place for T-cell-directed biologicals in the management of chronic plaque psoriasis will be for maintenance, rather than induction, of remission. This is a reflection of mode of action and relative safety for long-term administration.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: alefacept; anti-cd25; anti-cd28; anti-cd4; e-selectin; efalizumab

Document Type: Review Article

Affiliations: Dermatology Centre, Irving Building, Hope Hospital Salford, Manchester M6 8HD, UK.

Publication date: June 1, 2004

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more